


PHARMACEUTICAL 2023

CASSAVA SCIENCES INC Rank 34 of 446









RealRate

PHARMACEUTICAL 2023



CASSAVA SCIENCES INC Rank 34 of 446

The relative strengths and weaknesses of CASSAVA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CASSAVA SCIENCES INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of CASSAVA SCIENCES INC is the variable Other Expenses, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 260%, being 217% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	211,226
Cost of Goods Sold	0
Intangible Assets	622
Liabilities, Current	7,063
Liabilities, Non-Current	232
Other Assets	122
Other Compr. Net Income	0
Other Expenses	68,032
Other Liabilities	0
Other Net Income	997
Other Revenues	2,777
Property and Equipment	22,864
Research and Development	0
Selling, General and Administrative Expense	11,988

Output Variable	Value in 1000 USD
Assets	234,834
Liabilities	7,295
Expenses	80,020
Revenues	2,777
Stockholders Equity	227,539
Net Income	-76,246
Comprehensive Net Income	-76,246
Economic Capital Ratio	260%

